Personalized medicine and comparative effectiveness research in an era of fixed budgets
- Paul M. Brown
- … show all 1 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
For personalized medicine to be widely adopted in clinical practice, stakeholders need evidence of effectiveness, cost effectiveness and financial viability. Comparative effectiveness research (CER) using population based, retrospective data can inform assessments of personalized medicine. The purpose of this paper is to explore the potential and the limitations of CER. While the analytic methods and data used for CER overcome many of the disadvantages of randomized controlled trials, there are significant barriers, including lack of routinely collected genetic information, patient-reported outcomes and information on new and emerging technologies. Recommendations for using CER include augmenting current data with genetic information, promoting the collection of uniform health outcomes, using value of information analysis to guide development of new technologies, and greater use of decision analysis. Finally, in order to address stakeholder concerns regarding short term financial viability, additional emphasis should be devoted to cost analysis of implementation costs and overall financial impact.
- Meckley, L, Neuman, P (2010) Personalized medicine: factors influencing reimbursement. Health Policy 94: pp. 91-100 CrossRef
- Khoury, M, Rich, E, Randhawa, G, Teutsch, S, Niederhuber, J (2009) Comparative effectiveness research and genomic medicine: an evolving partnership for the 21st century medicine. Genet Med 10: pp. 707-711 CrossRef
- Davis J, Furstenthal L, Desai A, Norris T, Sutaria S, Fleming E, et al. The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat Rev Drug Discov. 2009;8:279–86.
- Deverka, P (2009) Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12: pp. 149-157 CrossRef
- Harmon A. My Genome, Myself: Seeking Clues in DNA. New York Times. 2007. November 17.
- Nellesen, D, Birnbaum, H, Greenberg, P (2010) Perspectives on comparative effectiveness research: views from diverse constituencies. Pharmacoeconomics 28: pp. 789-798 CrossRef
- Cook, J, Hunter, G, Vernon, J (2009) The future costs, risks and rewards of drug development: the economics of pharmacogenomics. Pharmacoeconomics 27: pp. 355-363 CrossRef
- Phillips, K, Liang, S, Van Bebbers, S (2008) Challenges to the translation of genomic information into clinical practice and health policy: utilization, preferences and economic value. Curr Opin Mol Ther 10: pp. 260-266
- Garber, A, Tunis, S (2009) Does comparative effectiveness research threaten personalized medicine?. N Engl J Med 360: pp. 1925-1927 CrossRef
- Conti R, Veenstra D, Armstrong K, Lesko L, Grosse S. Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost effectiveness and future research priorities. Med Decis Making. 2010;30:328–40.
- Epstein, R, Teagarden, J (2010) Comparative effectiveness research and personalized medicine: catalyzing or colliding?. Pharmacoeconomics 28: pp. 905-913 CrossRef
- Thomas, A, Phillips, A, Donnelly, R, Tak Piech, C (2010) Comparative effectiveness, personalized medicine and innovation: the path forward. Pharmacoeconomics 28: pp. 923-930 CrossRef
- Congressional Budget Office. Research on comparative effectiveness of medical treatments. Available at http://www.cbo.gov/ftpdocs/88xx/doc8891/12-18-ComparativeEffectiveness.pdf. Accessed July 20, 2010.
- Garrison, L, Carlson, R, Carlson, J, Kuszler, P, Meckley, L, Veenstra, DA (2008) A review of public policy issues in promoting the development and commercialization of pharmacogenomics applications. Challenges and implications. Drug Metab Rev 40: pp. 377-401 CrossRef
- McWilliams, A, Lutter, R, Nardinelli, C (2008) Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Personalized Med 5: pp. 281
- Centers for Disease Prevention and Control. Public Health Genomics. Available at http://www.cdc.gov/genomics/gtesting. Accessed on November 1, 2010.
- 23 and Me. Health Reports Complete List. Available at https://www.23andme.com/health/all/ Accessed on November, 2010.
- Ransohoff, D, Khoury, M (2009) Personal genomics: information can be harmful. Eur J Clin Investig 40: pp. 64-68 CrossRef
- Grosse, S, McBride, C, Evans, J, Khoury, M (2009) Personal utility and genomic information: look before you leap. Genet Med 11: pp. 575-576 CrossRef
- Rogowski, W, Grosse, S, Khoury, M (2009) Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 10: pp. 489-595 CrossRef
- Mega, JL, Close, SL, Wiviott, SD (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360: pp. 354-62 CrossRef
- Grossman, I, Lutz, M, Crenshaw, D, Saunders, AM, Burns, D, Roses, AD (2010) Alzheimer’s disease: diagnostics, prognostics and the road to prevention. EPMA J 1: pp. 293-303 CrossRef
- Panattoni L, Brown P, Te Ao B, Webster M, Gladding P. Personalised thienopyridine therapy: the cost effectiveness of genetic testing for CYP2C19 variants to guide treatment in patients with acute coronary syndromes. 2010. Under review.
- Meltzer, D, Basu, A, Conti, R (2010) The economics of comparative effectiveness studies. Pharmacoeconomics 28: pp. 843-853 CrossRef
- Grosse, S, Wordsworth, S, Payne, K (2008) Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 10: pp. 648-654 CrossRef
- Levy, A, Mitton, C, Johnston, K, Harigan, B, Briggs, A (2010) International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics 28: pp. 813-830 CrossRef
- Personalized medicine and comparative effectiveness research in an era of fixed budgets
The EPMA Journal
Volume 1, Issue 4 , pp 633-640
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Personalized medicine
- Comparative effectiveness
- Financial viability
- Cost effectiveness
- Paul M. Brown (1) (2)
- Author Affiliations
- 1. Lineberger Comprehensive Cancer Center & Institute of Pharmacogenomics and Individualized Therapies, University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
- 2. Department of Health Policy & Management, University of North Carolina, 1101e McGavran Greenberg, Chapel Hill, NC, 27599, USA